Regulus Therapeutics, the Carlsbad, CA-based developer of microRNA therapies, said today it has obtained an exclusive license from the lab of David Baltimore at Caltech to make drugs that affect a pair of microRNAs thought to be related to inflammation. Regulus is getting worldwide exclusive rights to develop drugs against miR-146 and miR-155. Baltimore is the chairman of Regulus’ scientific advisory board, and a member of the company’s board of directors. Financial terms of the deal weren’t disclosed.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
